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Background. Evidence is accumulating that circulating tumor cells (CTC) out of peripheral blood can serve as prognostic marker
not only in metastatic but also in early breast cancer (BC). Various methods are available to detect CTC. Comparisons between the
different techniques, however, are rare.Material andMethods.We evaluate two differentmethods forCTC enrichment and detection
in primary BC patients: the FDA-approved CellSearch System (CSS; Veridex, Warren, USA) and a manual immunocytochemistry
(MICC). The cut-off value for positivity was ≥1 CTC. Results. The two different nonoverlapping patient cohorts evaluated with
one or the other method were well balanced regarding common clinical parameters. Before adjuvant CHT 21.1% (416 out of 1972)
and 20.6% (247 out of 1198) of the patients were CTC-positive, while after CHT 22.5% (359 out of 1598) and 16.6% (177 out of
1066) of the patients were CTC-positive using CSS or MICC, respectively. CTC positivity rate before CHT was thus similar and not
significantly different (𝑃 = 0.749), while CTC positivity rate immediately after CHT was significantly lower usingMICC compared
to CSS (𝑃 < 0.001). Conclusion. Using CSS or MICC for CTC detection, we found comparable prevalence of CTC before but not
after adjuvant CHT.
1. Introduction
There is consistent data showing the prognostic relevance of
CTC in metastatic BC. A CTC count of ≥5 CTCs per 7.5mL
was significantly associated with shortened overall survival
(OS) and progression free survival (PFS) [1–4]. However,
there is limited data on the prognostic value of CTC in
early BC. Using the semi-automated detection method CSS
(Veridex, Warren, USA), we could show that the count of
CTC at the time of first diagnosis of an operable disease has
an influence on OS and PFS of patients with BC [5]. Recent
data proofed that CTC positivity predicted both decreased
PFS and OS in early BC [6].
CTC with epithelial characteristics are a rare event in
the peripheral blood of cancer patients both in terms of
absolute numbers (<10 cells/mL) and in terms of relative
numbers as compared to other blood cells (one CTC per
106–107 leukocytes) [7]. Various methods for isolation and
characterization of CTC are available that differ with regard
to enrichment, staining and detection [8] aswell as sensitivity,
specificity and reproducibility [9]. Currently used techniques
rely on a first cellular enrichment step to isolate CTC from
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other cell types such as red blood cells and leukocytes.
Physical (filters and density gradients) and immunomag-
netic approaches (magnetic affinity cell sorting, magnetic
beads and ferrofluid-based systems) are common examples
of cell enrichment methods [10]. Identification of CTC is
based on either direct cytometric methods using antibodies
such as immunocytochemistry (ICC), immunofluorescence
(IF), or flow cytometry (FACS), or indirect nucleic acid-
based methods which measure mRNA transcripts by reverse
transcriptase-polymerase chain reaction (RT-PCR) [9, 10].
Further technologies aim at higher sensitivity and better
phenotyping of CTC. Therefor evaluation and comparison
of different approaches is needed. CSS is a semi-automated
detectionmethod based on an immunomagnetic enrichment
using magnetic microbeads directed against the epithelial
marker EpCAM. This step is followed by an IF staining for
cytokeratin CK (CK8, CK18, CK19) and CD45 to distinguish
epithelial cells from leukocytes. A staining for nucleus acid
dye detects vital cells. After these automated preparation steps
the detection of CTC is done visually. Until today it is the only
CTC detection method which has been cleared by the U.S.
Food andDrug Administration for use in patient care [11, 12].
Using MICC for CTC detection the enrichment is based
on a density gradient centrifugation as in our study Onco-
Quick (Greiner BioOne, Frickenhausen, Germany), which
separates mononuclear cells from leukocytes and erythro-
cytes. It consists out of tubes with a porous barrier and
a separation medium. It is efficient for the enrichment of
CTC in the whole blood. A total of 1 × 106 mononuclear
cells are poured on a microscopic slide which is air dried.
Subsequently cells are stained for CK (CK8, CK18, CK19). No
staining for the nucleus or for CD45 is performed. CTC are
detected by conventional light microscopy.
In this study we detected CTC in a large patient cohort
with early BC before and after adjuvant CHT treated in
the SUCCESS A trial [13]. The aim of this analysis was
to evaluate CTC positivity rate and CTC load using two
different detectionmethods (CSS andMICC) in two different
not overlapping but comparable patient groups in order to
establish these methods for further patient care.
2. Patients, Material and Methods
2.1. Patients. Our patients’ collective was treated within the
SUCCESS A trial and defined as women with histologically
confirmed, invasive primary BC. All patients had either node
positive or high-risk node negative disease. Mastectomy or
breast conservation leading to R0 resection in all cases was
performed as primary surgery. 3754 patients were enrolled
in this German trial in a time period from 2005 to 2007.
All enrolled patients gave their informed written consent for
study inclusion and the research project. As a translational
research project CTC were assessed before and right after
CHT. The SUCCESS A trial is a multicenter, randomized
phase III study, which compared patients treatedwith 3 cycles
of 5-fluorouracil, epirubicin and cyclophosphamide (FEC)
followed by 3 cycles of docetaxel (D) every three weeks (q3w)
versus 3 cycles of FEC followed by 3 cycles of gemcitabine
(G) and docetaxel (D) q3w as CHT. Parameters analyzed
at primary diagnosis were the following: age, tumor stage,
nodal stage, histological grading, histological type, estrogen
(ER) and progesterone receptor (PR) status, HER2 status and
menopausal status.
Two different methods to detect CTC were prospectively
evaluated in two not overlapping but comparable patient
cohorts of the whole study population. Due to lack of
unlimited blood volume, samples were assigned to one or the
other method. Out of the 3754 patients randomized for the
clinical treatment studyCTCdetectionwas conducted in 3170
patients before CHT and in 2664 patients after CHT. Which
method was used for CTC detection was prearranged: CSS
was conducted for the first patients recruited (2000 patients
planned). If CSS was not available (e.g., due to technical
issues) and for the patients recruited later in the course of
the clinical trial MICC was conducted for CTC detection.
The patient selection process is illustrated in Figure 1. The
corresponding blood sample of one patient after CHT was
planned to be analyzed with the same method used for
the sample before CHT (blue and red cohort in Figure 1).
In order not to compromise statistical independency of the
two groups to be compared (blood samples analyzed for the
presence of CTC using either CSS or MICC), patients for
whom CTC presence was investigated using both methods
simultaneously were excluded from the analyses (22 cases
before chemotherapy, 8 cases after chemotherapy).
Both methods were used according to the manufac-
tures’ instructions with minor modifications (as described
below). The trial and the examination of blood samples were
approved by the local ethic committees and conducted in
accordance with the Declaration of Helsinki.
2.2. CTC Detection Using the CellSearch System. A total of
3570 samples (1972 samples before and 1598 after CHT)
were analyzed using the CSS (Veridex, Warren, USA), which
consists of the CellTracks AutoPrep System and the Cell-
Tracks Analyzer II. Prior to any therapy and right after CHT,
about 30mL of blood were collected into CellSave blood
collection tubes (Immunicon, Inc., Huntingdon Valley, PA,
USA) at the local site during routine blood drawby peripheral
vain puncture. These tubes are evacuated blood drawtubes
containing EDTA and a cellular preservative not described
in details by the supplier. The CellSave tubes were used to
maintain cell integrity and avoid cell degradation. The sam-
ples were then sent to the laboratory for tumor immunology
at the Department of Obstetrics and Gynecology, Klinikum
Innenstadt of the Ludwig-Maximilians-University (LMU),
Munich, Germany for further investigation. There they were
examined within a maximum of 96 h after blood drawing,
which is the time period for which the vendor guarantees
valid results after processing [14].
The samples were run with the Epithelial Cell Kit
(Veridex,Warren, USA) and the CellTracks AutoPrep System
as described before [15]. In brief, this system is based on
immunomagnetic enrichment with an EpCAM-antibody,
followed by labeling with monoclonal antibodies specific
for CK (CK8, CK18, CK19) and leukocytes (CD45). For
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Figure 1: Flow chart illustrating the patient selection process.
that, the CellSearch Epithelial Cell kit contains all required
reagents to conduct these steps: the ferrofluid particles
coated with anti-EpCAM antibodies for the immunomag-
netic enrichment, two phycoerythrin-conjugated antibodies
directed against CK to specifically identify epithelial cells,
a permeabilization buffer to allow CK antibodies entry into
epithelial cells, a nuclear dye [4,6-diamidino-2-phenylindole
(DAPI)] to fluorescently label the cell nuclei and an
antibody against CD45 conjugated with allophycocyanin
to identify leucocytes.
For the sample processing and evaluation the blood
contained in three CellSave tubes were pooled using a
ficoll density gradient. Then 7.5mL of enriched blood were
gently mixed with 6.5mL of dilution buffer, centrifuged
for 10min at 800 g at room temperature, and transferred
into the CellTracks AutoPrep System. The instrument
does all remaining steps automatically. The final volume
of 300 𝜇L containing enriched CTC is then transferred
automatically to a cartridge in a MagNest (magnetic
device for incubation) and is placed inside the MagNest cell
presentation chamber. After an incubation time of 20min to a
maximumof 24 h in the dark at room temperature, evaluation
of the samples was done using the CellTracks Analyzer II, a
semiautomated four-color fluorescencemicroscope.The cap-
tured images are presented in a picture gallery on a computer
screen. Two independent readers classified the cells according
to the following criteria: First, the staining patterns must
be consistent with that of an epithelial cell (cytokeratinphy-
coerythrin positive/DAPI positive/CD45-allophycocyanin
negative). Second, it has to be nearly round or oval with
a visible nucleus within the cytoplasm. Third, CTC must
have a minimum size of 4 𝜇m, however present with a large
heterogeneity regarding both CTC size andmorphology [14].
2.3. CTC Detection Using a Manual Immunocytochemistry.
The total number of samples analyzed using the MICC was
2264 (1198 samples before and 1066 samples after CHT). CTC
were isolated from an EDTA evacuated blood draw tube and
when available from the CellSave tube (total of 40mL blood).
The tumor cell enrichment was done by a density gradient
centrifugation with the OncoQuick (Greiner BioOne, Frick-
enhausen, Germany) system. Compared to Ficoll-Hypaque
(density of 1.077 g/mL), it uses a liquid separation medium
optimized for the specific enrichment of CTC and an addi-
tional membrane. Density gradient centrifugation separates
CTC and mononuclear cells from blood cells and granulo-
cytes. However, CTC can easily be lost using this technique
due to the presence of aggregates or to the migration of cells
to the plasma layer. OncoQuick however reduces the cross-
contamination of the different layers [10]. Cell separation was
performed according tomanufacturer’s protocol [16]. In brief,
precooled 50mL OncoQuick vials were overlaid with the
blood and centrifuged continuously for 25min at 1105 g and
6∘C. The entire volume of the compartment with interphase
cells was poured into a fresh centrifugation tube. Cells were
centrifuged twice with washing buffer (1 L PBS and 5 g of
bovine albumin) at 209 g for 10min at 6∘C without break. If
necessary red blood cells were lysed with lysis buffer (155mM
NH4Cl, 10mM KHC03, 0.1mM EDTA pH 7.2) according to
the recommendations of the supplier R & D systems. 1 × 106
mononuclear cells were spun onto a glass slide (cytospin),
using a cytocentrifuge (Hettich, Tuttlingen, Germany) [16].
2 out of a maximum of 6 cytospins as well as one negative
control (see below) were prepared from each blood sample.
In addition to be sure that the staining worked, each time a
positive control with cytospins containing MCF7 or SKBR3
cells (as available) were prepared. The slides were left to
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Figure 2: (a) shows images with CTC and artifacts from one patient presented in the gallery of the CSS. CTC show the characteristics defined
before: round or oval shape, positive signal in the cytokeratin channel (second column), intact nucleus (third column), overlapping of nucleus
and cytokeratin signal (first column), as well as no signal for CD45 as leucocytes marker (column 4), and in the negative control channel (fifth
column). In comparison (b) shows a sample of a CTC detected by theMICC. Cells which are labeled with the anti-cytokeratin-antibody A45-
B/B3 are then detected by the Z0259 antibody using the APAAP method and appear bright red.
air-dry overnight (12 to 24 h) at room temperature [17],
followed by staining or storage at −80∘C.
CTC detection was done by MICC, which is an open
system with respect to the selected antibodies. Staining was
performed using the anti-CK antibody A45-B/B3 (Micromet,
Munich, Germany), which recognizes CK8, CK18, and CK19
[18–20]. For the detection of CTC, an ICC staining based on
the alkaline phosphatase-antialkaline phosphatase (APAAP)
technique was performed using the Z0259 antibody (Dako)
as secondary antibody. Levamisole was taken for blocking
endogenous alkaline phosphatase [16]. For the negative
control the staining was done with the MOPC-21 antibody
(Mouse IgG1, k; Sigma) instead of A45-B/B3 and the sec-
ondary antibody. Afterwards the slides were sealed with cov-
erslips and stored at room temperature. Conventional light
field microscopy (Axiophot; Zeiss, Oberkochen, Germany)
was used for the detection of stained cells. The slides were
analyzed by two independent observers. CTC were defined
as bright red, round or oval shaped events with a minimum
of 4 𝜇m in size.
For both methods, the cut-off value for positivity was
≥1 CTC. Figure 2 shows sample pictures of both detection
methods.
2.4. Statistical Analyses. All statistical analyses were con-
ducted using the program IBM SPSS Statistics (Version 19).
𝑃-values below 0.05 were considered statistically significant.
Descriptive statistics for all categorical data are summa-
rized using frequency tables presenting absolute and relative
frequencies. All tests regarding comparisons of patient or
tumor characteristics between groups, associations between
patient or tumor characteristics and the prevalence of CTC,
or comparisons of CTC prevalence between methods were
conducted using the Chi-Square test for all categorical data.
Comparisons between groups regarding patient age were
performed with the Mann-Whitney-𝑈 test.
3. Results
3.1. CTC Prevalence before Chemotherapy. Before CHT 1972
samples were analyzed using CSS and 1198 using MICC,
in total 3170. The two patient cohorts were well balanced
with respect to the common baseline patient and clinical
parameters, which were listed in Table 1 (all 𝑃 > 0.15). The
majority of the patients showed pT1 or pT2 tumor stage, pN0
or pN1 nodal status andwas postmenopausal. Concerning the
histology most of the patients had a G2 or G3 histological
grading and a ductal invasive BC, a positive ER and PR status
as well as a negative HER2 status.
CTC positivity as assessed using CSS (21.1%) was sig-
nificantly associated with positive lymph node status (𝑃 <
0.001), but not with any other of the clinico-pathological
variables listed in Table 1 (all 𝑃 > 0.05). There was no
significant association between CTC positivity as assessed
by MICC and any of the clinico-pathological variables (all
𝑃 > 0.2).
In 1556 (78.9%) of the 1972 samples analyzed for the
presence of CTC before CHT using CSS, no CTC were
detected, while 416 (21.1%) were positive for CTC (median 1
CTC, range 1–827 CTC). 236 (12.0%) of the samples showed 1
CTC, and higher CTC loads were found in less than 10% of all
samples with 80 (4.1%), 21 (1.1%) and 19 (1.0%) of the samples
containing 2, 3 and 4 CTC respectively, while 5 CTC or more
were detected in only 60 (3.0%) of the samples (Figure 3).
Out of the 1198 samples investigated for the presence of
CTC before chemotherapy using MICCmethod, 951 (79.4%)
were negative for CTC. In the majority of the 247 (20.6%)
positive samples (median 1 CTC, range 1–256 CTC) only
1 CTC was detected (𝑛 = 148, 12.4%). Higher numbers
occurred in less than 9% of all samples, with 45 (3.8%), 20
(1.7%), 10 (0.8%) and 24 (2.0%) of the samples containing 2,
3, 4, and 5 or more CTC, respectively (Figure 3).
The CTC positivity rate before CHT as assessed by the
two methods did not differ significantly (CSS: 21.1% versus
MICC: 20.6%,𝑃 = 0.749).The distributions of CTC numbers
as detected before CHT using CSS or MICC are shown in
Figure 3. The two distributions were very similar and not
significantly different (𝑃 = 0.351).
3.2. CTC Prevalence after Chemotherapy. A total of 2664
blood samples were analyzed for the presence of CTC after
adjuvant CHT, with 1598 samples being investigated using
BioMed Research International 5
Table 1: Baseline characteristics of patients for whom CTC detection before adjuvant chemotherapy was performed using the Cell Search










pT1 818 (41.5%) 473 (39.5%)
pT2 1021 (51.8%) 640 (53.4%)
pT3 100 (5.1%) 66 (5.5%)
pT4 27 (1.4%) 16 (1.3%)
unknown 6 (0.3%) 3 (0.3%)
Nodal stage 0.8953
pN0 664 (33.7%) 418 (34.9%)
pN1 908 (46.0%) 545 (45.5%)
pN2 277 (14.0%) 165 (13.8%)
pN3 123 (6.2%) 70 (5.8%)
Histological grading 0.4573
G1 97 (4.9%) 59 (4.9%)
G2 931 (47.2%) 592 (49.4%)
G3 940 (47.7%) 544 (45.4%)
unknown 4 (0.2%) 3 (0.3%)
Histological type 0.1703
ductal 1590 (80.6%) 997 (83.2%)
lobular 238 (12.1%) 121 (10.1%)
other 140 (7.1%) 78 (6.5%)
unknown 4 (0.2%) 2 (0.2%)
Estrogen receptor status 0.6973
negative 589 (29.9%) 365 (30.5%)
positive 1380 (70.0%) 829 (69.2%)
unknown 3 (0.2%) 4 (0.3%)
Progesterone receptor status 0.1743
negative 678 (34.4%) 440 (36.7%)
positive 1289 (65.4%) 754 (62.9%)
unknown 5 (0.3%) 4 (0.3%)
HER2 status 0.8193
negative 1452 (73.6%) 886 (74.0%)
positive 483 (24.5%) 289 (24.1%)
unknown 37 (1.9%) 23 (1.9%)
Menopausal status 0.5603
premenopausal 822 (41.7%) 512 (42.7%)
postmenopausal 1150 (58.3%) 686 (57.3%)
Type of surgery 0.4073
breast conserving 1382 (70.1%) 856 (71.5%)
mastectomy 587 (29.8%) 340 (28.4%)
unknown 3 (0.2%) 2 (0.2%)
Adjuvant chemotherapy 0.9303
FEC-DG 968 (49.1%) 590 (49.2%)
FEC-DOC 1004 (50.9%) 608 (50.8%)
1All tests without unknowns.
2Mann-Whitney 𝑈 test.
3Chi-square test.
FEC-DG: 3 cycles of fluorouracil-epirubicin-cyclophosphamide followed by 3 cycles of docetaxel and gemcitabine; FEC-DOC: 3 cycles of fluorouracil-
epirubicin-cyclophosphamide followed by 3 cycles of docetaxel.

















Figure 3: Distribution of the number of CTC detected before
chemotherapy using the CellSearch System (CSS, black bars; 𝑛 =
1972) or manual immunocytochemistry (MICC, gray bars; 𝑛 =
1198).
CSS and 1066 samples being investigated usingMICC. Again,
the two groups were well balanced with respect to the
common baseline patient and clinical parameters, which are
listed in Table 2 (all 𝑃 > 0.05).
No CTC were found in 1239 (77.5%) of the 1598 samples
analyzed for the presence of CTC afterCHTusing theCSS.Of
the 359 (22.5%) CTC positive samples (median 1 CTC, range
1–124 CTC), 217 (13.6%) samples had 1 CTC, 68 (4.3%) had
2 CTC, 26 (1.6%) had 3 CTC, 14 (0.9%) had 4 CTC, and 34
(2.1%) had 5 or more CTC (Figure 4).
889 (83.4%) of the 1066 samples investigated for the
presence of CTC after CHT using MICC were negative for
CTC and CTC were found in the remaining 177 (16.6%)
samples (median 1 CTC, range 1–23 CTC). One CTC was
detected in 107 (10.0%) samples, 2 CTC in 40 (3.8%) samples,
3 CTC in 11 (1.0%) samples, 4 CTC in 9 (0.8%) samples and 5
or more CTC in 10 (0.9%) samples (Figure 4).
The CTC positivity rate after CHTwas significantly lower
when assessed using MICC (16.6%) as compared to the CTC
positivity rate after CHT assessed using CSS (22.5%, 𝑃 <
0.001). Accordingly, the distributions of CTC numbers as
detected after CHT using CSS or MICC were significantly
different (𝑃 = 0.005; see Figure 4).
In contrast to CTC positivity before CHT, CTC positiv-
ity after CHT as assessed using CSS was not significantly
associated with nodal stage (𝑃 = 0.107). However, contrary
to the situation before CHT, a significant association was
found between CTC positivity after CHT determined with
CSS and HER2 status of the primary tumor (𝑃 = 0.044),
with a higher proportion of HER2 positive tumors among the
CTC positive samples (105 out of 252; 41.7%) as compared to
the CTC negative samples (293 out of 921; 31.8%).There were

















Figure 4: Distribution of the number of CTC detected after
chemotherapy using the CellSearch System (CSS, black bars; 𝑛 =
1598) or manual immunocytochemistry (MICC, gray bars; 𝑛 =
1066).
as assessed by CSS and any of the other clinico-pathological
parameters listed in Table 2 (all 𝑃 > 0.1).
Similar to samples with CTC positivity being assessed
using CSS, there was a significant association between CTC
positivity after CHT as assessed using MICC and the HER2
status of the tumor (𝑃 = 0.048), with a higher proportion of
HER2 positive tumors among the CTC positive samples (48
out of 123; 39.0%) as compared to the CTC negative samples
(185 out of 688; 26.9%). No other significant associations
between CTC positivity after CHT as assessed using MICC
and clinico-pathological parameters listed in Table 2 were
found (all 𝑃 > 0.1).
3.3. CTC Prevalence before and after Chemotherapy. In 2225
patients blood samples were analyzed for the presence of
CTC using the samemethod before and after CHT (CSS: 1481
patients;MICC: 744 patients). Regardless of themethod used,
most patients had no CTC in their blood at both time points
(CSS: 62.3%; MICC: 66.0%) and in only a small proportion
CTC were detected before and after CHT (CSS: 5.1%; MICC
3.2%). For samples analyzed using CSS the proportion of
patients that were CTC negative before and CTC positive
after CHT was higher as compared to samples analyzed with
MICC (CSS: 17.4%;MICC: 13.0%). In contrast, the proportion
of patients with CTC before but no CTC after CHTwas lower
in the CSS group (CSS: 15.3%; MICC: 17.7%). Figure 5 shows
the proportions of patients in the four possible categories
regarding CTC presence or absence before and after CHT
(i.e., CTC negative both before and after CHT; CTC negative
before and CTC positive after CHT, CTC positive before
and CTC negative after CHT, CTC positive both before and
after CHT) when the CTC analyses at both time points were
performed with either CSS or MICC. The proportions of
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Table 2: Baseline characteristics of patients for whom CTC detection after adjuvant chemotherapy was performed using the Cell Search










pT1 660 (41.3%) 440 (41.3%)
pT2 824 (51.6%) 549 (51.5%)
pT3 86 (5.4%) 62 (5.8%)
pT4 22 (1.4%) 11 (1.0%)
unknown 6 (0.4%) 4 (0.4%)
Nodal stage 0.5613
pN0 544 (34.0%) 383 (35.9%)
pN1 731 (45.7%) 475 (44.6%)
pN2 221 (13.8%) 151 (14.2%)
pN3 102 (6.4%) 57 (5.3%)
Histological grading 0.6913
G1 72 (4.5%) 48 (4.5%)
G2 770 (48.2%) 531 (49.8%)
G3 751 (47.0%) 483 (45.3%)
unknown 5 (0.3%) 4 (0.4%)
Histological type 0.9193
ductal 1290 (80.7%) 864 (81.1%)
lobular 191 (12.0%) 122 (11.4%)
other 113 (7.1%) 77 (7.2%)
unknown 4 (0.3%) 3 (0.3%)
Estrogen receptor status 0.9683
negative 482 (30.2%) 322 (30.2%)
positive 1113 (69.6%) 741 (69.5%)
unknown 3 (0.2%) 3 (0.3%)
Progesterone receptor status 0.5873
negative 549 (34.4%) 377 (35.4%)
positive 1045 (65.4%) 686 (64.4%)
unknown 4 (0.3%) 3 (0.3%)
HER2 status 0.0773
negative 1173 (73.4%) 811 (76.1%)
positive 398 (24.9%) 233 (21.9%)
unknown 27 (1.7%) 22 (2.1%)
Menopausal status 0.7753
premenopausal 688 (43.1%) 453 (42.5%)
postmenopausal 910 (56.9%) 613 (57.5%)
Type of surgery 0.6473
breast conserving 1134 (71.0%) 747 (70.1%)
mastectomy 461 (28.8%) 316 (29.6%)
unknown 3 (0.2%) 3 (0.3%)
Adjuvant chemotherapy 0.6243
FEC-DG 780 (48.8%) 510 (47.8%)
FEC-DOC 818 (51.2%) 556 (52.2%)
1All tests without unknowns.
2Mann-Whitney 𝑈 test.
3Chi-square test.
FEC-DG: 3 cycles of fluorouracil-epirubicin-cyclophosphamide followed by 3 cycles of docetaxel and gemcitabine; FEC-DOC: 3 cycles of fluorouracil-
epirubicin-cyclophosphamide followed by 3 cycles of docetaxel.















Figure 5: CTC prevalence before and after chemotherapy for
patients whose blood sampleswere analyzed for the presence of CTC
using either the CellSearch System (CSS, black bars; 𝑛 = 1481) or
manual immunocytochemistry (MICC, gray bars; 𝑛 = 744) at both
time points.
patients in the four categories differed significantly between
the two methods (𝑃 = 0.006).
4. Discussion
We evaluated CTC prevalence in peripheral blood of patients
with early BC treated within the SUCCESS A trial before
and after CHT in two different but comparable and well-
balanced patient cohorts of the entire study-population using
two different methods for CTC detection. We found ≥1
CTC/30mL blood in 416 (21.1%) patients before and in 359
(22.5%) patients after CHT using the semi-automated CSS.
Using the MICC we detected ≥1 CTC/2 × 106 mononuclear
blood cells (tow cytospins) in 247 (20.6%) patients before
and in 177 (16.6%) patients after CHT. CTC positivity rate
before CHT as assessed based on CSS was associated with
a positive lymph-node status, while CTC positivity rate as
assessed using MICC was not associated with any of the
investigated clinical parameters. CTC positivity rate after
CHT was associated with a positive HER2 status both for
samples analyzed with CSS and MICC.
The CTC positivity rate as determined based on the two
different methods was very similar before CHT (21.1% versus
20.6%). In contrast, the CTC positivity rate after CHT was
considerably and significantly higher in samples analyzed
using CSS as compared to samples analyzed using MICC
(22.5% versus 16.6%).
Overall, detection rates for CTC in peripheral blood were
reported in the range from 0.6% to 100% [19, 21–27]. This
immense variability may be due to the broad diversity of
detectionmethodswhich often lack a specific standardization
and quality control. More recent data obtained from patients
withmetastatic BC using both immunocytochemical [1, 4, 22,
25, 28] and molecular techniques [4, 29] suggest a positivity
range of 30% to 50% for a CTC positivity cut-off ≥5, and 65%
to 85% for a CTC positivity cut-off ≥1 [30–33].
Only limited data exist onCTCprevalence in the adjuvant
setting or during follow up period. However, compared to
the metastatic situation these studies indicate an even lower
prevalence of about 24% to 38% (cut-off ≥1 CTC with CSS)
making the detection of CTC even more difficult [6, 34].
In patients with stage I or II BC only about 10% have ≥1
CTC/23mL blood as stated by Wicha and Hayes [35]. Our
results obtained with two different methods (CTC positivity
rates of 21.1% by CSS and 20.6% by MICC before CHT, less
than 10% of the patients having more than 1 CTC) are very
similar to these reported values.
In our study we found comparable positivity rates before
but not after CHT using CSS or MICC respectively. One
possible explanation for the higher CTC positivity rate after
CHT comparing CSS with MICC might be the detection
of dormant cells which might not be affected by CHT.
Furthermore, Aktas et al. propose that the persistence of CTC
might be associated with stem cell like tumor cells and that
these cells may undergo phenotypic changes, described as
EMT, which enables them to escape conventional CHT [29].
This is however contradicting to the assumption, that these
cells might not be detected by CSS (see below). Another
hypothesis could be that CTC are somehow affected by CHT
and as cell aggregates or smaller cells are lost using the
OncoQuick enrichment method. Further investigations are
needed to proof or neglect these theories.
A huge variety of different analytical systems for CTC
isolation and detection has been developed in recent years,
and attempts have beenmade to standardize preparation pro-
tocols and to increase assay efficiency. Two steps (isolation-
enrichment and detection) are combined in most cases to
identify CTC. Most of them include a separation step based
on size (density gradient or filters) or biological character-
istics (expression of epithelial- or cancer-specific markers),
followed by the detection using ICC ormolecular assays [36].
The most reliable and clinical significant results have
been so far obtained using CSS as CTC detection method,
which was one of the methods we evaluated. CSS is a semi-
automated detection device, which importantly minimizes
the source of technical failures and therefore reduces tech-
nical variability in comparison to a manual method. It is
based on a combination of ICC and IF where specificmarkers
for CTC, such as CK and EpCAM are linked to nuclear
and leukocyte staining CSS has been validated in a broad
clinical testing program. So far this technology has produced
the largest amount of clinical data regarding CTC in BC.
Different ring experiments with CSS showed very good and
comparable results in the participating centers [14, 37]. In
addition the supplier offers an online training every 4months
to evaluate its own results. In conclusion, CSS looks like a
more reliable method compared to others because of the
high standardization, the CD45 counterstaining and clearly
defined selection criteria.
Nevertheless there are also some restrictions associated
with the system: it is an enrichment and imaging method
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only, non-offering the opportunity to further characterize
the cells on a molecular level. Moreover, the number of
markers available per run is limited to DAPI, CK, CD45,
leaving only one additional channel free for one addi-
tional marker (usually HER2). Another main disadvantage
is the cell enrichment based on EpCAM only. Not all CTC
express the same cell-surface antigens (such as EpCAM)
and a significant subpopulation of CTC shows epithelial-
mesenchymal transition (EMT)/cell stem cell (CSC) traits.
Therefore enrichment methods based on EpCAM may miss
these cells and underestimate the number of CTC [38–40].
Concerning MICC, several alternative protocols, differ-
ent in fixatives, buffers, incubation times and antibodies,
have been proposed and used [16]. In our study in order to
standardize the detection of tumor cells by ICC we followed
the protocol published by Fehm et al. [41]. It is important
to mention that in order to save time and reduce costs, only
two slides per patient were analyzed. Therefore it might be
that CTC have been missed and the total CTC load has
been underestimated: thismay explain the lower cell numbers
found using MICC compared to CSS (range before CHT: 1–
256 versus 1–827, range after CHT: 1–23 versus 1–124). These
differences though were not significant, since the majority of
the samples contain only a low CTC load (median 1 CTC)
as detected with one or the other method. However it is also
possible to get false positive results since the MICC is lacking
a CD45 counterstaining for leucocytes. The detection itself is
quite simple though and gives no room for doubtful results,
since the stained cells appear bright red.
Further characterization of CTC by use of classic ICC
techniques is possible according to the investigators pref-
erence. Visual observation of stained CK-positive epithelial
CTC and quantification of the staining for every single cell for
different markers can provide new insights into tumor biol-
ogy.Thus,MICC opens a variety of possibilities to phenotype
CTC and to correlate these results with the morphology of
the cells. Detecting the expression of predictive markers such
as HER2, ER and other markers simultaneously [42–44] as
well as deregulated pathways such as the PI3K/AKT-kinase
pathway or phosphorylated EGFR to phenotype CTC further
by using MICC are promising research fields [45]. These
steps are required as the utilization of biomarkers for BC
treatment is evolving with a high pace [46–48]. In addition,
the confirmation of EMT/stem cell marker expression such as
CD133 or Twist and vimentin in CTC may proof the theory
that a subpopulation of CTC shows stem cell characteristics
and may play a key role in the metastatic process [49].
PCR based methods, image-based approaches, microfil-
ter and microchip devices are new technical improvements
in CTC detection and characterization.The AdnaTest Breast-
Cancer (Adna-Gen AG, Langenhagen, Germany), which is
a PCR based CTC analysis method, shows an equivalent
sensitivity to CSS detecting ≥2 CTC [9]. Using AdnaTest it is
possible to detect very low numbers of CTC by detecting the
expression of tumor associated genes, which is one advantage
compared to CSS [36]. Further AdnaTest allows the detection
of different additional markers such as ER, PR and EMT-
or CSC-markers [50, 51] offering the possibility to further
characterize the biology andmolecular abnormalities of CTC
to better understand the metastasizing process as well as to
conduct personalized CTC directed cancer treatment [9].
However, AdnaTest does not allow a correlation with the cell
morphology or with the number of cells. Since an immediate
proceeding of the samples is required, it is no approach
suitable for a multicenter setting.
Limitations of our study are that we evaluated two very
different CTC detection methods, which differ with respect
to the enrichment, the identification and the blood volume
used. Further we compared the two methods in two different
non-overlapping patient populations of the entire patient
collective treated within the SUCCESS A trial. However the
analyzes was done with very large patient numbers (𝑛 =
3170 before CHT and 𝑛 = 2664 after CHT) and the patient
cohorts were well-balanced concerning the common clinico-
pathological parameters.
5. Conclusion
The detection of CTC in BC is a research field of high
clinical interest and impact. The prognostic relevance in the
metastatic setting is well demonstrated. Data in the adjuvant
situation however is still limited. CTC detection in early
BC is impaired by low positivity rate and low cell numbers.
There exist a huge variety of detectionmethods with different
advantages and disadvantages. In our study we evaluated the
semi-automated CSS andMICC and found comparable CTC
positivity rates before but not after adjuvant CHT in two
different not overlapping but well-balanced cohorts of patient
with early BC. Currently the CSS is regarded as the gold
standard for CTC detection in studies aiming at investigating
the prognostic value of CTC and should be further evaluated
in clinical trials. However, characterization and phenotyping
of CTC is crucial to deepen our understanding of metastases
formation. Open systems as MICC used in our study offer
the possibility to phenotype CTC and compare the marker
expression with the cell morphology. In conclusion, the
different approaches for CTC detection complement each
other and may provide different insights in tumor biology.
Highly standardized preparation protocols and high assay
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MRD: Minimal residual disease
OS: Overall survival
PFS: Progression free survival
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